Jason C. Breen

Jason C. Breen

Jason C. Breen

Jason Breen is a partner in Goodwin’s Technology Companies & Life Sciences Group. He represents start-up and later-stage companies in the software, technology and life sciences industries throughout their corporate life cycle, with a particular focus on mergers, acquisitions, divestitures, financings and other strategic transactions. He also represents venture capital, growth equity and private equity funds focusing on technology and life sciences companies.

Professional Experience

Prior to joining Goodwin in 2011, Mr. Breen was an associate in the corporate group at Simpson Thacher & Bartlett in New York.

Areas of Practice


Mr. Breen’s representation of startup and later-stage companies includes pre-incorporation planning, general company representation and counseling, venture capital financings, public offerings, joint ventures and mergers and acquisitions.

Representative Matters

Mergers and Acquisitions
  • AppNexus, an ad tech company, in its acquisitions of Open AdStream, YieldEx, MediaGlu and Realmedia Latin America
  • Virtustream, a cloud management firm, in its sale to EMC
  • Promedior, a clinical stage immunotherapy company, in its grant to Bristol-Myers Squibb of an exclusive right to acquire Promedior
  • Teva Pharmaceuticals, a pharmaceutical company, in its sale of its animal health business to Bayer Healthcare and its sale of four targeted oncology development programs to Ignyta
  • Interactions, a technology company, in its acquisition of the AT&T Watson technology program
  • Bomgar, a provider of enterprise remote support solutions, in TA Associates’ majority investment in Bomgar
  • Numara Software, a provider of integrated IT management solutions, in its sale to BMC Software
  • MyoKardia, a company developing precision therapies for genetic heart disease, in its $46 million financing
  • Phreesia, a healthcare point-of-service platform, in its $30 million financing led by LLR Partners
  • Global Blood Therapeutics, a biopharmaceutical company developing therapeutics for the treatment of severe blood disorders, in its $48 million financing



J.D., 2007
UCLA School of Law
B.A., 2002
Harvard University



New York
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers